Letters to the Editor

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands;
Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands;
Stavanger University Hospital-Rogaland Hospital, Stavanger, Norway;
Oslo Myeloma Center, Oslo, Norway;
Albert Schweitzer Hospital, Dordrecht, the Netherlands;
St Olavs Hospital and Norwegian University of Science, Trondheim, Norway;
Maasstad Hospital, Rotterdam, the Netherlands;
Meander Medical Center, Amersfoort, the Netherlands;
Førde Central Hospital, Førde, Norway;
Skanes University Hospital Lund, Scania, Sweden;
Herlev Hospital, Herlev, Denmark;
NU-Hospital, Uddevalla Hospital, Uddevalla, Sweden;
Rijnstate Hospital, Arnhem, the Netherlands;
Aalborg Hospital, Aalborg, Denmark;
Aarhus University Hospital, Aarhus, Denmark;
Rigshospitalet Copenhagen, Copenhagen, Denmark;
Sahlgrenska University Hospital, Gothenburg Sweden;
Haga Hospital, Den Haag, the Netherlands;
Sodra Alvsborgs Sjukhus Boras, Boras, Sweden;
Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands;
Radboud Medical Center, Nijmegen, the Netherlands;
Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands;
Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands;
Skanes University Hospital Lund, Scania, Sweden;
Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands;
Department of Haematology, AgeCare, Odense University Hospital, Odense, Denmark
Haematologica Early view Feb 13, 2020 https://doi.org/10.3324/haematol.2019.240374